ClinicalTrials.gg
CompletedNCT04241393Updated Nov 17, 2020

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

A Phase 1 interventional study of Tavapadon tablet and Tavapadon [14C] suspension in Healthy Subjects, sponsored by Cerevel Therapeutics, LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2020, 6 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of [14C] tavapadon.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Cerevel Therapeutics, LLC is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 1 (5%) have results posted.

First submitted before Cerevel Therapeutics, LLC became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects, ages 18 to 55 years, inclusive, at the time of signing the form (ICF).
  2. (BMI) of 18.0 to 32.0 kg/m2 and a total body weight > 50 kg (110 lbs).
  3. In good health, determined by no findings from medical history, physical examination, 12-lead (ECG), vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is not acceptable) at Screening or Check-in as assessed by the investigator (or designee).
  4. Male subjects with a pregnant or a nonpregnant partner of must agree to use an acceptable or a highly effective method of from signing of informed consent during the trial, and for 7 days following the last dose of study drug.
  5. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
  6. Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.
  7. Capable of consuming the standard diet.
  8. History of a minimum of 1 bowel movement per day.

Exclusion criteria

Exclusion Criteria:

  • Medical History and Concurrent Diseases
  1. Has a history of psychotic symptoms requiring treatment with an antipsychotic medication within the 12 months prior to signing ICF.
  2. Subjects with epilepsy, or history of epilepsy, or conditions that lower seizure threshold, seizures of any etiology (including substance or drug withdrawal), or who have increased risk of seizures as evidenced by history of electroencephalogram with epileptiform activity. Subjects with a history of febrile seizures and/or history of head trauma with loss of consciousness requiring hospitalization overnight will be excluded as well.
  3. Subjects with a current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, hematological, immunological, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either subject safety or the results of the trial.

    Medical conditions that are minor or well controlled may be considered acceptable if the condition does not expose the subject to an undue risk of a significant AE or interfere with the assessments of safety during the course of the trial. The medical monitor should be contacted in any instance where the investigator is uncertain regarding the stability of a subject's medical conditions(s) and the potential impact of the condition(s) on trial participation.

  4. Any condition possibly affecting drug absorption including history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed; cholecystectomy and bariatric weight loss surgeries will not be allowed).
  5. History of substance or alcohol-use disorder (excluding nicotine; , 5th edition criteria) within 2 years prior to signing the ICF.
  6. History of regular alcohol consumption exceeding 14 drinks/week [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor] within 6 months prior to signing ICF.
  7. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.
  8. Subjects who answer "yes" on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR

    Subjects who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR

    Subjects who, in the opinion of the investigator, present a serious risk of suicide.

  9. Subjects who have attempted suicide in the past.

    • Physical Examination and Clinical Laboratory Results
  10. Positive hepatitis panel ( surface antigen and virus antibody) and/or positive test (HIV-1 and HIV-2 antibody) at Screening.
  11. Positive urine drug screen (with cotinine) or positive alcohol breathalyzer at Screening and Check-in. Subjects with a positive drug screen for illicit drugs or cotinine are excluded and may not be retested or rescreened. Subjects with a positive urine drug screen resulting from use of marijuana (any cannabinoids), prescription medications, over-the-counter medications, or products that, in the investigator's documented opinion, do not signal a clinical condition that would impact the safety of the subject or interpretation of the trial results may continue evaluation for the trial following consultation and explicit approval by the medical monitor.
  12. Subjects with a 12-lead demonstrating the following:

    • corrected for heart rate using Fridericia's formula >450 msec (average of 3 ECGs obtained at the Screening Visit).
  13. Subjects with any of the following abnormalities in clinical laboratory tests at the Screening Visit, confirmed by a single repeat measurement, if deemed necessary, and at the discretion of the investigator:

    • (AST) or alanine aminotransferase (ALT) ≥2 × (ULN)
    • Total ≥1.5 × ULN.
  14. Subjects with other abnormal laboratory test results, vital sign results, or ECG findings unless, based on the investigator's judgment, the findings are not medically significant and would not impact the safety of the subjects or the interpretation of the trial results. The medical monitor should be contacted to discuss individual cases, as needed.

    Tests with exclusionary results should be repeated to ensure reproducibility of the abnormality before excluding a subject based on criteria provided in the protocol. For ECGs, 3 consecutive recordings are required and if 2 of the 3 remain exclusionary, then the subject is not eligible for the trial.

    • Disallowed Prior and Concomitant Medications
  15. Subjects taking other prohibited medication or who would be likely to require prohibited concomitant therapy during the trial.

    • Other
  16. Subjects with difficulty swallowing.
  17. Subjects who are known to be allergic or hypersensitive to the IMP or any of its components.
  18. Subjects who are known to be allergic or hypersensitive to contents of the standard diet.
  19. Subjects who have participated in any clinical trial involving administration of an drug (new chemical entity) in the past 30 days or 5 half-lives (if known) prior to dosing.
  20. Receipt of blood products within 2 months prior to Check-in.
  21. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to Screening, or from 6 weeks prior to Screening.
  22. Poor peripheral venous access.
  23. Subjects with exposure to significant diagnostic or therapeutic radiation (eg, serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to Check-in.
  24. Subjects who have participated in a radiolabeled drug trial where exposures are known to the investigator within the previous 4 months prior to admission to the clinic for this trial or participated in a radiolabeled drug trial where exposures are not known to the investigator within the previous 6 months prior to admission to the clinic for this trial. The total 12-month exposure from this trial and a maximum of 2 other previous radiolabeled trials within 4 to 12 months prior to this trial will be within the CFR recommended levels considered safe, per US Title 21 CFR 361.1: less than 5,000 mrem whole body annual exposure with consideration given to the half-lives of the previous radiolabeled trial drugs received.
  25. Any subject who, in the opinion of the sponsor, investigator, or medical monitor, should not participate in the trial.
  26. Subjects who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the investigator.
  27. Unwilling or unable to comply with the lifestyle modifications described in this protocol.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Tavapadon

    Drug: Tavapadon tablet · Drug: Tavapadon [14C] suspension

Interventions

  • Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily \[QD\] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)

  • Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of \[14C\] Tavapadon on Day 16

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of [14C]-Tavapadon and Metabolites: Area under the radioactivity time curve from zero to infinity (AUCinf) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood

    Time frame: Day 16 up to Day 28

  2. Pharmacokinetics of [14C]-Tavapadon and Metabolites: Area under the radioactivity time curve from time 0 to last quantifiable concentration (AUClast) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood

    Time frame: Day 16 up to Day 28

  3. Pharmacokinetics of [14C]-Tavapadon and Metabolites: Peak radioactivity Cmax) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood

    Time frame: Day 16 up to Day 28

  4. Pharmacokinetics of [14C]-Tavapadon and Metabolites: Time to last measurable radioactivity (Tlast) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood

    Time frame: Day 16 up to Day 28

  5. Pharmacokinetics of [14C]-Tavapadon and Metabolites: Time to maximum radioactivity (Tmax) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood

    Time frame: Day 16 up to Day 28

  6. Pharmacokinetics of [14C]-Tavapadon and Metabolites: elimination half-life (t½) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood

    Time frame: Day 16 up to Day 28

  7. Pharmacokinetics of Tavapadon: Apparent total body clearance (CL/F) for Tavapadon

    Time frame: Day 16 up to Day 28

  8. Pharmacokinetics of Tavapadon: Apparent volume of distribution (Vz/F) for Tavapadon

    Time frame: Day 16 up to Day 28

  9. Ratio of Plasma AUCinf for Tavapadon to whole blood total Radioactivity AUCinf

    Time frame: Day 16 up to Day 28

  10. Ratio of Plasma AUCinf for Metabolites (PF-06752844) to whole blood total Radioactivity AUCinf

    Time frame: Day 16 up to Day 28

  11. Ratio of plasma AUCinf for Metabolites (PF-06752844) to plasma AUCinf for Tavapadon

    Time frame: Day 16 up to Day 28

  12. Ratio of whole blood AUCinf for Tavapadon (and metabolites, measured as total radioactivity) to plasma AUCinf for Tavapadon (and metabolites, measured as total radioactivity)

    Time frame: Day 16 up to Day 28

  13. Pharmacokinetics of [14C]-Tavapadon: Total radioactivity in urine at different intervals

    Time frame: Day 16 up to Day 28

  14. Pharmacokinetics of [14C]-Tavapadon: Cumulative radioactivity excreted in urine (Cumulative Aeu)

    Time frame: Day 16 up to Day 28

  15. Pharmacokinetics of [14C]-Tavapadon: Fraction of the dose administered excreted in urine (Feu) for total radioactivity at different intervals

    Time frame: Day 16 up to Day 28

  16. Pharmacokinetics of [14C]-Tavapadon: Cumulative fraction of the dose administered excreted in urine (Cumulative Feu) for total radioactivity in urine

    Time frame: Day 16 up to Day 28

  17. Pharmacokinetics of [14C]-Tavapadon: Amount eliminated in feces (Aef) for total radioactivity in feces at different intervals

    Time frame: Day 16 up to Day 28

  18. Pharmacokinetics of [14C]-Tavapadon: Cumulative amount excreted in feces (Cumulative Aef) for total radioactivity in feces

    Time frame: Day 16 up to Day 28

  19. Pharmacokinetics of [14C]-Tavapadon: Fraction of the dose administered excreted in feces (Fef) for total radioactivity in feces at different intervals

    Time frame: Day 16 up to Day 28

  20. Pharmacokinetics of [14C]-Tavapadon: Cumulative Fraction of the dose administered excreted in feces (Cumulative Fef) for total radioactivity in feces

    Time frame: Day 16 up to Day 28

Secondary outcomes

  1. Number of Subjects with reported Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 28

  2. Number of subjects with Clinically significant changes in Electrocardiogram measures (PR,RR,QT and QTcF)

    Time frame: Up to Day 28

  3. Number of subjects with Clinically meaningful changes in Vital signs (Systolic and Diastolic blood pressures, heart rate, respiratory rate and body temperature)

    Time frame: Up to Day 28

  4. Number of subjects with clinically significant changes in laboratory measures

    Time frame: Up to Day 28

  5. Change from baseline of the Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

    Time frame: At Baseline and up to Day 28

07

Study locations

1 site
  • Covance Clinical Research Unit, Inc.
    Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Nov 2020, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2020
First posted
Jan 27, 2020
StartActual
Feb 4, 2020
Primary completionActual
Nov 8, 2020
CompletionActual
Nov 8, 2020
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04241393
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Feb 4, 2020
Primary completion
Nov 8, 2020
Completion
Nov 8, 2020
Last update
Nov 17, 2020

Study contacts

Matthew Leoni, MD
study director · Cerevel Therapeutics, LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion